Oh... I thought he was a driver and was squatting at a mamak store and kept ordering roti and telor.


Apple2353 MrsLim.. why upset about Legend. he only knows the word CABUTTTTT..every counter also he said CABUTTTTTT
06/12/2021 4:41 PM

Cabut where? Your boss calling?

The average driver salary in the United Kingdom is £23,675 (RM132,000) per year

If your drebar salary is less than RM11,000 per month, please complain to Andy Hall about ESG issues.


Legend CABUTTTTTTTT!!!
06/12/2021 4:29 PM

https://www.bursamalaysia.com/misc/missftp/sblnt/NetShortPosition20211202.pdf

RSS list as at 2nd December 2021.

Syndicates out from ATA.

The following companies will be at risk of attacks.

Short Name | Long Name | Total NS Position (Volume) | % of Total NSPosition

INARI | INARI AMERTRON BERHAD | 36,374,899 | 0.98
GTRONIC | GLOBETRONICS TECHNOLOGY BHD | 4,981,234 | 0.74
PENTA | PENTAMASTER CORPORATION BERHAD | 5,017,499 | 0.70
VS | V.S. INDUSTRY BERHAD | 12,565,586 | 0.33
SKPRES | SKP RESOURCES BERHAD | 5,230,550 | 0.33

Dyson's EBITDA increased by 18% to £1.3 billion (RM7.267 billion) for FY2020.

It's EBITDA/Revenue was 22.81%.

However ATAIMS' EBITDA/Revenue was only 5.98% (lowest compared to VS and SKP). The low margins were probably due to pricing squeeze and dependence on Dyson.

ATAIMS, VS and SKP all have EPF/Salaries ratios of less than 12%, indicating high percentages of foreign workers in the industry.

Where can Dyson switch to when ATAIMS was already the lowest cost supplier???


_____________________________________________________

+++ Dyson FY2020
Revenue: £5.7 billion (RM31.86 billion) (increased 6%)
EBITDA: £1.3 billion (RM7.267 billion) (increased 18%)
EBITDA/Revenue: 22.81%


+++ ATA IMS FY 2021

Revenue : RM4,221.815M
EBITDA : RM252.398M
PBT : RM192.038M
PAT : RM150.300M
Wages, salaries and others: RM367.649M
Contrib to state plan: RM13.004M

EBITDA/Revenue: 5.98%
Salaries/Revenue: 8.71%
EPF/Salaries: 3.54%


+++ VS FY 2021

Revenue : RM4,002.281M
EBITDA : RM438.587M
EBIT : RM337.116M
PBT : RM329.130M
Profit after MI : RM245.351M
Wages, salaries and others : RM464.0688M
Contrib to state plans : RM20.377M

EBITDA/Revenue: 10.96%
Salaries/Revenue: 11.6%
EPF/Salaries: 4.39%


+++ SKP FY2021

Revenue : 2,251.182M
EBITDA : RM206,898M
EBIT : RM171,590M
PBT : RM171,322M
PAT : RM133,243M
Wages, salaries and others : RM187.218M
Contrib to state plans : RM9.812M

EBITDA/Revenue: 9.19%
Salaries/Revenue: 8.32%
EPF/Salaries: 5.24%

Just for argument sake that the arrangement can work, the implication is that RDIF will be purchasing from a rent-seeker. RDIF's costs will be higher. Do you think Mr Kirill Dmitriev will allow it? Do you seriously think such a proposal will get past the receptionist counter?

Take a look at RDIF's management at https://rdif.ru/Eng_Team/

Mr Kirill Dmitriev, the CEO or RDIF, entered Stanford University at the age of 16. He holds a BA in Economics with Honors and Distinction from Stanford University and an MBA with High Distinction (Baker Scholar) from the Harvard Business School. Mr Dmitriev worked as an investment banker at Goldman Sachs in New York and a consultant at McKinsey & Company in Los Angeles, Moscow, and Prague, before returning to Russia in 2000.

So, the import and export licences and custom documentations will just show RDIF and China manufacturers? So what's the role Ucrest?

With a staff strength of 10 (3 Malays, 7 Indians from India), none of them is fluent in Russian or Mandarin, what exactly can they do?


joyvest thats why i am saying, from what was announced yesterday that they dont require license , they are insinuating that RDIF will buy directly from china manufacturers managed by ucrest.

As said, Sedania and Dataprep are different. It's a situation of gamblers buying and selling among themselves. The number of shares are limited.

Ucrest has taken advantage of the relaxation of private placement issuance percentage from 10% to 30%. They just want to dump 100-200M PP and ESOS shares, both in Ucrest and Key Asic.



Universe Bursa is a casino, if the Botak's intention is to blow up price then you may follow up and follow sell when it goes down. No stock is safe.

Sedania just play up without any cause is worst bec we are all in the dark. I actually saw it started moving up just 2 c yest, but dare not to buy.
21/05/2021 11:14 AM

Prescribed drugs cannot be ordered online. There are strict licenses, distribution and storage procedures to follow.


Universe Mrs Lim, the sellers in shopee and lazarda don't have to have any licence to sell products they just order from another sellers at lower cost to send to the buyers. I think this is Botak's concept, and don't see anything wrong with it.

It's call money laundering, falsification of accounts, insider trading and market manipulation!


joyvest Imedic is just developed to justify the payment (outflows) out of the country to the Development company overseas...whether it is useful or workable , no body cares................
21/05/2021 11:02 AM
00

Sedania and Dataprep did not issue false statements and did not give any Facebook Live presentations. Sedania and Dataprep did not break the law. Ucrest broke the law

BIG DIFFERENCE!


Universe After Sedania shot up for no reason, and also Dataprep still about 1.00, tells me that we dont needs to be so serious about stock market. Just buy at your own risks.
21/05/2021 10:58 AM

Ok, I thought you were talking about iMedic, the software portal that does not work.

On the licensing question, Bursa has already asked and Ucrest basically said 'Malaysia no need'.


6) The relevant regulatory approvals, permits and/or licenses required to be obtained by UCrest in connection with the Agreements. To also state whether UCrest has secured any of these regulatory approvals, permits and/or licences, and the relevant dates of application and approval.6) The relevant regulatory approvals, permits and/or licenses required to be obtained by UCrest in connection with the Agreements. To also state whether UCrest has secured any of these regulatory approvals, permits and/or licences, and the relevant dates of application and approval.



Universe Ucrest has licence to sell e-medic, vaccines can be sent from the manufacturers direct to Russia with Ucrest name like what they do in website e-commerce sellers. The sellers would not disclose where they get the products, to prevent buyers go direct to them.

I'm impressed with the way questions were put across by Bursa. Well done Team Bursa!

The real questions were:

1) Ucrest Board of Directors (in the plural form implying jointly and severally), when is the date of commencement of each agreement? (Please take your time to think carefully before you answer. Remember what happened on the 18th of May 2021 at 8pm)

Ucrest: uhm... 19th?


3) One of the key elements of an agreement is consideration. Without that key element, the agreement is null and void. So, tell us, what is the price of the vaccines?

Ucrest: still working on my spreadsheet lah


4) I have to ask this question even though you do not have an answer, what are the names of the contract manufacturers?

Ucrest: shows middle finger


5) The export of Sputnik's cultured virus cells from Russia and the import of cultured virus cells into China; and the export of manufactured vaccines from China to whichever destination countries will surely require regulatory approvals, permits and/or licenses in those respective countries; for whatever manner that Ucrest is a party to the agreement. Tell us when and how the regulatory approvals, permits and/or licenses have been obtained.

Ucrest: Malaysia no need

RDIF has already entered into agreement, directly, with 3 contact manufacturers in China:

Shenzhen Yuanxing Gene-tech Co
TopRidge Pharma, a subsidiary of Tibet Rhodiola Pharmaceutical Holding
Hualan Biological Bacterin Inc

It's public information. Nothing 'business and political confidential' about it.

Universe,

If an agreement with named counter-party can be false, what more unknown parties.

Anyway, Ucrest broke the law on 3 occasions in releasing unaudited forecast & targets via Facebook and still have yet to reveal the same to Bursa.



A listed corporation can disclose the Forecasts & Targets provided that the disclosure adheres to the Corporate Disclosure Policy prescribed under the ACE LR including the requirement that there should not be selective disclosure of the Forecasts & Targets to the investors, press or analysts prior to the release or simultaneous release, of the Forecasts & Targets through Bursa Link.

9.15 ​Prohibition from trading
​ ​
​Insiders must not trade on the basis of material information which is not known to the investing public.

9.16 Content of press or other public announcement
​ ​
​(1) ​The content of a press or other public announcement is as important as its timing. A listed corporation must ensure that each announcement -
​ ​ ​

​(v) ​the presentation of revenue or profit estimate, forecast or projection without sufficient qualification, assumptions or factual basis. If any revenue or profit estimate, forecast or projection is released, it must be prepared carefully, with a reasonable factual basis and be stated realistically, with appropriate assumptions and qualifications, so as to ensure that it is properly understood. In addition, the accounting bases and calculations of the estimate, forecast or projection and the assumptions must be reviewed by the external auditors except where the revenue or profit estimate, forecast or projection is required to be released on an immediate basis; FAQ 9.1, FAQ 9.2, FAQ 9.7, FAQ 9.8